Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Children/adolescents with attention-deficit/hyperactivity disorder (ADHD) may have a poor or inadequate response to psychostimulants or be unable to tolerate their side-effects; furthermore, stimulants may be inappropriate because of co-existing conditions. Only one non-stimulant ADHD pharmacotherapy, the noradrenaline transporter inhibitor atomoxetine, is currently approved for use in Europe. We review recent advances in understanding of the pathophysiology of ADHD with a focus on the roles of catecholamine receptors in context of the α2A-adrenergic receptor agonist guanfacine extended release (GXR), a new non-stimulant treatment option in Europe. Neuroimaging studies of children/adolescents with ADHD show impaired brain maturation, and structural and functional anomalies in brain regions and networks. Neurobiological studies in ADHD and medication response patterns support involvement of monoaminergic neurotransmitters (primarily dopamine and noradrenaline). Guanfacine is a selective α2A-adrenergic receptor agonist that has been shown to improve prefrontal cortical cognitive function, including working memory. The hypothesized mode of action of guanfacine centres on direct stimulation of post-synaptic α2A-adrenergic receptors to enhance noradrenaline neurotransmission. Preclinical data suggest that guanfacine also influences dendritic spine growth and maturation. Clinical trials have demonstrated the efficacy of GXR in ADHD, and it is approved as monotherapy or adjunctive therapy to stimulants in Canada and the USA (for children and adolescents). GXR was approved recently in Europe for the treatment of ADHD in children and adolescents for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. GXR may provide particular benefit for children/adolescents who have specific co-morbidities such as chronic tic disorders or oppositional defiant disorder (or oppositional symptoms) that have failed to respond to first-line treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Stress signalling pathways that impair prefrontal cortex structure and function
Arnsten, A. F. T. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2648 · Cited by 3,299
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Castellanos, F. X. (2002) · JAMA · doi:10.1001/jama.288.14.1740 · Cited by 1,646
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies
Cortese, S., Kelly, C., Chabernaud, C., Proal, E., Di Martino, A., Milham, M. P., & Castellanos, F. X. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101521 · Cited by 1,067 · cited 7×
“Resting-state fMRI data have shown dysfunctional con- nectivity in the DMN in affected children/adolescents and adults versus controls, which supports the hypothesis that ADHD is related to delayed or disrupted maturation of the DMN [31, 32, 35, 48–50].”
BackgroundInfluentialCandidate gene studies of ADHD: a meta-analytic review
Gizer, I. R., Ficks, C., & Waldman, I. D. (2009) · Human Genetics · doi:10.1007/s00439-009-0694-x · Cited by 1,020
Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory
Vijayraghavan, S., Wang, M., Birnbaum, S. G., Williams, G. V., & Arnsten, A. F. T. (2007) · Nature Neuroscience · doi:10.1038/nn1846 · Cited by 1,013
Structure-stability-function relationships of dendritic spines
Kasai, H., Matsuzaki, M., Noguchi, J., Yasumatsu, N., & Nakahara, H. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00162-0 · Cited by 847
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Hart, H., Radua, J., Nakao, T., Mataix-Cols, D., & Rubia, K. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.277 · Cited by 764
European clinical guidelines for hyperkinetic disorder ? first upgrade
Taylor, E., D�pfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1002-x · Cited by 682
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672
Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007
Larson, K., Russ, S. A., Kahn, R. S., & Halfon, N. (2011) · Pediatrics · doi:10.1542/peds.2010-0165 · Cited by 580
Volkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · cited 1×
“Human and primate PET studies indicate that MPH binds predominantly to DATs in the striatum [141, 142].”
BackgroundTreatment of ADHD in children with tics: A randomized controlled trial
The Tourette’s Syndrome Study Group (2002) · Neurology · doi:10.1212/wnl.58.4.527 · Cited by 504
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 1×
“5) [15, 16], and MPH is generally recommended in Europe as the first choice medication for children/adolescents with ADHD [2, 13].”
Backgroundthe ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
Self-citationKasper, L. J., Alderson, R. M., & Hudec, K. L. (2012) · Clinical Psychology Review · doi:10.1016/j.cpr.2012.07.001 · Cited by 414 · cited 1×
“The disorder is associated with deficits in executive function [6], including working memory [7], and leads to impairment in a broad range of academic and social activities [2].”
BackgroundJensen, C. M., & Steinhausen, H.-C. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0142-1 · Cited by 402
Sallee, F. R., Mcgough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318191769e · Cited by 391
Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391 · cited 1×
“Improvement in attention, working memory and learning with guanfacine has been demonstrated in animal studies [74, 106–115].”
Resultvan Ewijk, H., Heslenfeld, D. J., Zwiers, M. P., Buitelaar, J. K., & Oosterlaan, J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.01.003 · Cited by 377
Lesch, K.-P., Timmesfeld, N., Renner, T. J., Halperin, R., Röser, C., Nguyen, T. T., Craig, D. W., Romanos, J., Heine, M., Meyer, J., et al. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0119-3 · Cited by 374 · cited 1×
“Pooled molecular genetics data support the involvement in genes coding for regulators of synaptic plasticity, including CTNNA2 and KALRN, and cell adhesion molecules in ADHD [95].”
BackgroundSobanski, E., Banaschewski, T., Asherson, P., Buitelaar, J., Chen, W., Franke, B., Holtmann, M., Krumm, B., Sergeant, J., Sonuga‐Barke, E., et al. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02217.x · Cited by 365
Self-citationArnsten, A. F., & Dudley, A. G. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-2 · Cited by 363
Sjöwall, D., Roth, L., Lindqvist, S., & Thorell, L. B. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12006 · Cited by 359 · cited 1×
“Emotional dysregulation 11–66 % [253–258] No data found”
BackgroundAtypical default network connectivity in youth with attention-deficit/hyperactivity disorder
Fair, D. A., Posner, J., Nagel, B. J., Bathula, D., Dias, T. G. C., Mills, K. L., Blythe, M. S., Giwa, A., Schmitt, C. F., & Nigg, J. T. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.003 · Cited by 354 · cited 1×
“Resting-state fMRI data have shown dysfunctional connectivity in the DMN in affected children/adolescents and adults versus controls, which supports the hypothesis that ADHD is related to delayed or disrupted maturation of the DMN [31, 32, 35, 48–50].”
Hippocampus and Amygdala Morphology in Attention-Deficit/Hyperactivity Disorder
Plessen, K. J., Bansal, R., Zhu, H., Whiteman, R., Amat, J., Quackenbush, G. A., Martin, L., Durkin, K., Blair, C., Royal, J., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.795 · Cited by 347 · cited 1×
“Morphological and volumetric changes of subcortical structures, including the thalamus, basal ganglia and limbic system have also been reported [30, 40–42].”
BackgroundNewcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
Cortese, S., Holtmann, M., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Graham, J., Taylor, E., Sergeant, J., et al. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12036 · Cited by 336 · cited 4×
“Stimulants in particular may cause sleep disturbances if administered in the evening so should be administered at this time only very cautiously [19, 219], whereas GXR can be administered either in the morning or in the evening [179].”
BackgroundInfluentialCortese, S. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.01.009 · Cited by 335
Cerebellar development and clinical outcome in attention deficit hyperactivity disorder
Mackie, S., Shaw, P., Lenroot, R., Pierson, R., Greenstein, D. K., Nugent, T. F., Sharp, W. S., Giedd, J. N., & Rapoport, J. L. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.4.647 · Cited by 333
Volkow, N. D., Wang, G.-J., Newcorn, J., Telang, F., Solanto, M. V., Fowler, J. S., Logan, J., Ma, Y., Schulz, K., Pradhan, K., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.932 · Cited by 331
Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome
Freeman, R. D., & Tourette Syndrome International Database Consortium (2007) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-007-1003-7 · Cited by 318
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317
Sallee, F. R., Lyne, A., Wigal, T., & McGough, J. J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0080 · Cited by 306
The Child and Adolescent Twin Study in Sweden (CATSS)
Anckarsäter, H., Lundström, S., Kollberg, L., Kerekes, N., Palm, C., Carlström, E., Långström, N., Magnusson, P. K. E., Halldner, L., Bölte, S., et al. (2011) · Twin Research and Human Genetics · doi:10.1375/twin.14.6.495 · Cited by 300
GREENHILL, L. L., SWANSON, J. M., VITIELLO, B., DAVIES, M., CLEVENGER, W., WU, M., ARNOLD, L. E., ABIKOFF, H. B., BUKSTEIN, O. G., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00012 · Cited by 287
Bloch, M. H., Panza, K. E., Landeros-Weisenberger, A., & Leckman, J. F. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b26e9f · Cited by 270
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A. (2008) · CNS Spectrums · doi:10.1017/s1092852900017107 · Cited by 270 · cited 2×
“Indeed, dose-dependent sedative effects are well described but tend to be transient [172, 173, 175, 182].”
BackgroundMeta-analysis of fMRI studies of timing in attention-deficit hyperactivity disorder (ADHD)
Hart, H., Radua, J., Mataix-Cols, D., & Rubia, K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.08.003 · Cited by 258
Spencer, T. J., Greenbaum, M., Ginsberg, L. D., & Murphy, W. R. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0152 · Cited by 257
CHAPPELL, P. B., RIDDLE, M. A., SCAHILL, L., LYNCH, K. A., SCHULTZ, R., ARNSTEN, A., LECKMAN, J. F., & COHEN, D. J. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199509000-00010 · Cited by 250
Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?
SPENCER, T. J., BIEDERMAN, J., HARDING, M., O'DONNELL, D., FARAONE, S. V., & WILENS, T. E. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00014 · Cited by 238
Hannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E., & Ding, Y.-S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.017 · Cited by 236
Update on Environmental Risk Factors for Attention-Deficit/Hyperactivity Disorder
Froehlich, T. E., Anixt, J. S., Loe, I. M., Chirdkiatgumchai, V., Kuan, L., & Gilman, R. C. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0221-3 · Cited by 236
Gamo, N. J., Wang, M., & Arnsten, A. F. T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.06.015 · Cited by 232
Stimulant Medication and Substance Use Outcomes: A Meta-analysis
Humphreys, K. L., Eng, T., & Lee, S. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1273 · Cited by 221 · cited 1×
“By inference and despite a meta-analysis that demonstrated no association between stimulant use and increased SUD risks [213], GXR could provide a useful additional treatment option for patients who are at particularly high risk of SUD, unable to abstain from substance misuse despite stimulant treatment, or those with…”
ADHD and the Prefrontal Cortex
Arnsten, A. F. T. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.01.018 · Cited by 220 · cited 4×
“Nonetheless, all empirically effective medications seem to enhance signalling of dopamine and/or noradrenaline in the CNS (Table 1) [72].”
BackgroundInfluentialArnsten, A. F. T. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm033 · Cited by 200
Greven, C. U., Bralten, J., Mennes, M., O’Dwyer, L., van Hulzen, K. J. E., Rommelse, N., Schweren, L. J. S., Hoekstra, P. J., Hartman, C. A., Heslenfeld, D., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3162 · Cited by 198
Swanson, J. M., & Volkow, N. D. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00433-8 · Cited by 173
Nonpharmacological Treatments for ADHD: A Meta-Analytic Review
Hodgson, K., Hutchinson, A. D., & Denson, L. (2014) · Journal of Attention Disorders · doi:10.1177/1087054712444732 · Cited by 168
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Mood lability and psychopathology in youth
Stringaris, A., & Goodman, R. (2009) · Psychological Medicine · doi:10.1017/s0033291708004662 · Cited by 162 · cited 1×
“Emotional dysregulation 11–66 % [253–258] No data found”
BackgroundHuss, M., Hölling, H., Kurth, B.-M., & Schlack, R. (2008) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-008-1006-z · Cited by 159 · cited 1×
“ADHD affects approximately 5 % of children and adolescents worldwide [3, 4] and symptoms persist into adulthood in most cases [5].”
BackgroundMeta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine
BANGS, M. E., TAUSCHER-WISNIEWSKI, S., POLZER, J., ZHANG, S., ACHARYA, N., DESAIAH, D., TRZEPACZ, P. T., & ALLEN, A. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815d88b2 · Cited by 152
Uhlén, S., & Wikberg, J. E. S. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90299-6 · Cited by 141
Aoki, C. (1998) · Cerebral Cortex · doi:10.1093/cercor/8.3.269 · Cited by 138 · cited 1×
“common subtype found in the PFC [68].”
Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors
Dai, H., Kaneko, K., Kato, H., Fujii, S., Jing, Y., Xu, A., Sakurai, E., Kato, M., Okamura, N., Kuramasu, A., et al. (2007) · Neuroscience Research · doi:10.1016/j.neures.2006.10.020 · Cited by 136 · cited 1×
“ciated with arousal, learning and memory [86–88].”
Spencer, T. J., Faraone, S. V., Surman, C. B. H., Petty, C., Clarke, A., Batchelder, H., Wozniak, J., & Biederman, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2459 · Cited by 127
Executive Dysfunction in School-Age Children With ADHD
Lambek, R., Tannock, R., Dalsgaard, S., Trillingsgaard, A., Damm, D., & Thomsen, P. H. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710370935 · Cited by 125
Ramos, B. P., Stark, D., Verduzco, L., van Dyck, C. H., & Arnsten, A. F. T. (2006) · Learning & Memory · doi:10.1101/lm.298006 · Cited by 124 · cited 1×
“Moderate stimulation of a2A-adrenergic receptors in the PFC improves working memory in animal models and humans [69, 74, 75].”
BackgroundStriatal Creatine and Glutamate/Glutamine in Attention-Deficit/Hyperactivity Disorder
Carrey, N. J., MacMaster, F. P., Gaudet, L., & Schmidt, M. H. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0008 · Cited by 117 · cited 1×
“Recent evidence suggests that dysfunction in the glutamatergic neurotransmitter system plays a role in the pathophysiology of ADHD [78].”
BackgroundSchulz, K. P., Fan, J., Bédard, A.-C. V., Clerkin, S. M., Ivanov, I., Tang, C. Y., Halperin, J. M., & Newcorn, J. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2053 · Cited by 114 · cited 4×
“Human fMRI and arterial spin labelling MRI data also indicate common spatial patterns of brain activity after administration of MPH and ATX [160, 161].”
BackgroundInfluentialNoradrenergic modulation of space exploration in visual neglect
Malhotra, P. A., Parton, A. D., Greenwood, R., & Husain, M. (2006) · Annals of Neurology · doi:10.1002/ana.20701 · Cited by 114
Sorkin, E. M., & Heel, R. C. (1986) · Drugs · doi:10.2165/00003495-198631040-00003 · Cited by 106 · cited 1×
“GXR does not cause hypertension or affect cardiac re-polarization but may reduce heart rate and blood pressure [131].”
BackgroundConnor, D. F., Grasso, D. J., Slivinsky, M. D., Pearson, G. S., & Banga, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0119 · Cited by 102
Methylphenidate Increases Cortical Excitability via Activation of Alpha-2 Noradrenergic Receptors
Andrews, G. D., & Lavin, A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300818 · Cited by 101 · cited 1×
“Data from in vitro and in vivo animal studies suggest that both MPH and ATX may indirectly stimulate D1 and a2-adrenergic receptors on post-synaptic neurons in the PFC [157–159].”
BackgroundConnor, D. F., Findling, R. L., Kollins, S. H., Sallee, F., López, F. A., Lyne, A., & Tremblay, G. (2010) · CNS Drugs · doi:10.2165/11537790-000000000-00000 · Cited by 101 · cited 1×
“placebo) significantly reduced oppositional symptoms among children aged 6–12 years with ADHD and co-morbid oppositional symptoms [174], and was associated with significantly greater reduction in oppositional subscale scores than was ATX (p = 0.”
BackgroundHong, S.-B., Zalesky, A., Fornito, A., Park, S., Yang, Y.-H., Park, M.-H., Song, I.-C., Sohn, C.-H., Shin, M.-S., Kim, B.-N., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.013 · Cited by 99
Locomotor hyperactivity induced by blockade of prefrontal cortical α2-adrenoceptors in monkeys
Ma, C.-L., Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.004 · Cited by 96
Sagvolden (2006) · Behavioral and Brain Functions · doi:10.1186/1744-9081-2-41 · Cited by 94
Xia, S., Li, X., Kimball, A. E., Kelly, M. S., Lesser, I., & Branch, C. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2012.04.011 · Cited by 92 · cited 1×
“Reduced volume and integrity of white matter tracts between the thalamus and striatum, hippocampus and PFC have been demonstrated in children with ADHD versus controls [42].”
BackgroundWang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84 · cited 1×
“Suboptimal response to stimulant 11–44 % [144, 232–236] N/A”
BackgroundKessler, D., Angstadt, M., Welsh, R. C., & Sripada, C. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3156-14.2014 · Cited by 83
Ludolph, A. G., Kassubek, J., Schmeck, K., Glaser, C., Wunderlich, A., Buck, A. K., Reske, S. N., Fegert, J. M., & Mottaghy, F. M. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.02.025 · Cited by 83
Self-citationTourette Syndrome and comorbid ADHD: Current pharmacological treatment options
Rizzo, R., Gulisano, M., Calì, P. V., & Curatolo, P. (2013) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2013.01.005 · Cited by 76 · cited 1×
“The benefit of a2-adrenergic receptor agonists on both ADHD and co-morbid tic disorders has been demonstrated in a number of studies [190–193].”
BackgroundSonuga-Barke, E. J. S., Coghill, D., Wigal, T., DeBacker, M., & Swanson, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0024 · Cited by 71
Hains, A. B., Yabe, Y., & Arnsten, A. F. T. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2015.01.001 · Cited by 70
McAllister, T. W., McDonald, B. C., Flashman, L. A., Ferrell, R. B., Tosteson, T. D., Yanofsky, N. N., Grove, M. R., & Saykin, A. J. (2011) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2011.06.022 · Cited by 70 · cited 2×
“Early data suggest that guanfacine may have beneficial effects in the treatment of attention disorders associated with neurological conditions [225–227].”
BackgroundRåstam, M., Täljemark, J., Tajnia, A., Lundström, S., Gustafsson, P., Lichtenstein, P., Gillberg, C., Anckarsäter, H., & Kerekes, N. (2013) · The Scientific World Journal · doi:10.1155/2013/315429 · Cited by 70
Uhlén, S., Muceniece, R., Rangel, N., Tiger, G., & Wikberg, J. E. S. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb00161.x · Cited by 59
Effects of α-2A adrenergic receptor agonist on time and risk preference in primates
Kim, S., Bobeica, I., Gamo, N. J., Arnsten, A. F. T., & Lee, D. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2520-0 · Cited by 47
Faraone, S. V., McBurnett, K., Sallee, F. R., Steeber, J., & López, F. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.005 · Cited by 44
van Zwieten, P. A., & Chalmers, J. P. (1994) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877397 · Cited by 43
Schulz, K. P., Clerkin, S. M., Fan, J., Halperin, J. M., & Newcorn, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2893-8 · Cited by 35
Findling, R. L., McBurnett, K., White, C., & Youcha, S. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0103 · Cited by 32 · cited 1×
“oppositional symptoms among children/adolescents (aged 6–17 years) with ADHD and oppositional symptoms (Table 4) [201].”
BackgroundWang, M., Tang, Z.-X., & Li, B.-M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.062 · Cited by 31 · cited 1×
“Improvement in attention, working memory and learning with guanfacine has been demonstrated in animal studies [74, 106–115].”
ResultKawaura, K., Karasawa, J.-I., Chaki, S., & Hikichi, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.044 · Cited by 29
Ren, W.-W., Liu, Y., & Li, B.-M. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.10.001 · Cited by 23
Cited by
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
“In Europe, guanfacine extended-release (GXR), an alfa-2 adrenergic agonist, is licensed for the treatment of children and adolescents with ADHD for whom stimulants are not suitable, not tolerated or where shown to be ineffective [256,257].”
BackgroundEvidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders · doi:10.1177/1087054719836159 · Cited by 62
Garcia-Argibay, M., Li, L., Du Rietz, E., Zhang, L., Yao, H., Jendle, J., Ramos-Quiroga, J. A., Ribasés, M., Chang, Z., Brikell, I., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105076 · Cited by 52
“…during the follow-up period (methylphenidate: N06BA04, amphetamine: N06BA01, dexamphetamine: N06BA02, atomoxetine: N06BA09, lisdexamfetamine: N06BA12) from the PDR. Guanfacine (C02AC02) was not included as, in Sweden, it was not approved for the treatment of ADHD until 2016 (Huss et al., 2016).”
Iwanami, A., Saito, K., Fujiwara, M., Okutsu, D., & Ichikawa, H. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12979 · Cited by 44
Metadata
- Authors
- Huss, M., Chen, W., & Ludolph, A. G.
- Venue
- Clinical Drug Investigation
- Published
- 2015-11-20
- Volume
- 36
- Issue
- 1
- Pages
- 1-25
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W2179646396
- Cited by
- 56
- References
- 95
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.